Key Takeaway: Precision BioSciences has reported its first quarter 2024 financial results, highlighting that its wholly owned programs are on track for Clinical Trial Application (CTA) and Investigational New Drug (IND) submissions. The PBGENE-HBV program targeting Hepatitis B is expected to submit in 2024, while PBGENE-PMM for primary mitochondrial myopathy is anticipated in 2025. Additionally, the first ARCUS in vivo gene editing program has opened for enrollment in the UK.
Price reaction · baseline $10.64 (2024-05-10 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+8.1%
day 1
+9.2%
day 3
+12.6%
Market Sentiment Analysis
POSITIVE FACTORS
Wholly owned programs are on track for CTA and IND submissions.
PBGENE-HBV aims for Hepatitis B virus treatment in 2024.
PBGENE-PMM is set for primary mitochondrial myopathy in 2025.
First ARCUS in vivo gene editing program is now enrolling.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Wholly owned programs on track for CTA and/or IND submissions – PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 – First ARCUS in vivo gene editing program now open for enrollment in the United Kingdom through partnered OTC deficiency program;
Frequently Asked Questions
What are the key programs reported by Precision BioSciences?
Precision BioSciences highlighted PBGENE-HBV for Hepatitis B and PBGENE-PMM for primary mitochondrial myopathy.
When is the PBGENE-HBV program expected to submit?
The PBGENE-HBV program is on track for submission in 2024.
What is the status of the ARCUS gene editing program?
The first ARCUS in vivo gene editing program is now open for enrollment in the UK.
What financial results did Precision BioSciences report?
Precision BioSciences reported its first quarter 2024 financial results, focusing on program progress.